Full-Time
Senior Director
Patient Reported Outcomes
Posted on 10/31/2025
Revolution Medicines
1,001-5,000 employees
Clinical-stage oncology company developing RAS inhibitors
Compensation Overview
$236k - $295k/yr
San Carlos, CA, USA
Hybrid
Hybrid role; onsite at Redwood City, CA HQ.
 Biology & Biotech (2) |
|---|
| , |
- Ph.D. or equivalent degree in a relevant discipline (e.g., psychology, psychometrics, outcomes research, public health) or those who possess a clinical doctorate (M.D., Pharm.D.) coupled with a master’s degree.
- A minimum of 13 years of related experience, including a minimum of 6 years of leadership in the pharmaceutical industry, regulatory or CRO space.
- Strong ability to work effectively across broad matrix teams and the ability to influence and align with senior leadership.
- Experience with the application of patient-reported outcome measures in hematology and oncology areas.
- Experience conducting observational research involving patient-reported outcome data collection and the interpretation and communication of results to key stakeholders.
- Experience with patient-reported outcome requirements for regulatory and health technology assessment/reimbursement agencies, including deep working understanding of the FDA Patient-Reported Outcomes Guidance.
- Knowledge of development and validation of clinical outcome assessment measures.
- Understanding of health care markets and regulatory and reimbursement decision making, especially in relation to the global use of PRO data.
- Be abreast of rapidly changing methodological and regulatory environment.
- Strong analytical and synthesis skills.
- Demonstrated ability to understand and communicate with matrix teams.
- Define strategic execution roadmap and develop metrics to assess impact of PROs on business value and patient outcomes. Will work across internal stakeholders, Revolution Medicines leadership and external groups to drive patient-centered solutions.
- Maximize the impact of evidence of treatment benefit by providing input to briefing packages, publication strategies, and market access strategy.
- Be an ambassador and promote the importance of PROs’ role to quantitative and qualitative COA across senior leadership.
- Lead PRO/COA governance structure and align cross-functional stakeholders across development, medical, commercial, and access functions.
- Lead the preparation of relevant sections of documents and communications for regulatory agency meetings, support and/or participate in said meetings at regulatory agencies, and provide robust evidence in support of submission activities.
- Oversee the dissemination of results from clinical trials as well as PRO development and validation studies that are aligned with publication strategy.
- Participate in global external collaborations regarding policies, standards, and use of measures (e.g., PRO Consortium, BIO PFDD Task Force, EuroQol Group, ISPOR working groups).
- Participate in creating and delivering education on measures for internal business partners.
- Guide operations staff in securing licenses and commissioning translations/adaptations for instruments in a timely manner.
- Knowledge of the drug development process within hematology/oncology preferred.
Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Simplify's Take
What believers are saying
- Daraxonrasib Phase 3 RASolute 302 data supports FDA approval filing with priority review.
- Zoldonrasib demonstrated 52% ORR and 11.1-month PFS in KRAS G12D NSCLC at AACR 2026.
- Multi-drug pipeline addresses 30% of cancers with RAS mutations across pancreatic, lung, colorectal.
What critics are saying
- Daraxonrasib's broad RAS targeting causes Grade 3+ rashes in 13% of patients, triggering FDA review.
- Emergent resistance via RAS flux amplification nullifies daraxonrasib efficacy in Phase 3 trials.
- Amgen's Lumakras and Mirati's adagrasib dominate KRAS G12C market, blocking elironrasib penetration.
What makes Revolution Medicines unique
- Tri-complex inhibitor mechanism targets diverse RAS mutations competitors cannot address.
- Daraxonrasib achieved 13.2-month median OS versus 6.7-month chemotherapy in pancreatic cancer.
- Proprietary platform from Martin Burke's natural product synthesis enables rapid compound optimization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -1%Revolution Medicines announced that its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial, nearly doubling survival time and reducing death risk by 60% compared to chemotherapy. Patients taking the daily pill typically survived 13.2 months versus 6.7 months with chemotherapy. The drug targets RAS mutations found in approximately 90% of pancreatic cancer cases. CEO Mark Goldsmith called the results "unprecedented", noting no drug has previously shown an overall survival benefit exceeding one year in Phase 3 pancreatic cancer trials. Revolution Medicines plans to seek FDA approval using a Commissioner's National Priority Voucher for expedited review. The approval would apply to second-line treatment for patients whose cancer progressed on other therapies. A separate Phase 3 trial for newly diagnosed patients is ongoing.
Sasse spotlight on potential pancreatic cancer cure. health April 11, 2026 health pancreatic cancer drug development RAS mutations Revolution Medicines' experimental drug daraxonrasib is showing promise as a potential breakthrough treatment for pancreatic cancer, garnering attention and driving up the company's stock. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, a drug that targets RAS mutations, which are present in about 90% of pancreatic cancer cases. The company anticipates releasing results from a Phase 3 trial soon, and it may become the first targeted treatment for this aggressive cancer. This development has significantly boosted RevMed's stock, increasing by nearly 185% over the past year, also making the company a prime acquisition target, according to reports. The drug gained recent attention when former Senator Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer, disclosed he is taking daraxonrasib. Sasse reported to The New York Times that his tumors have shrunk by 76% since starting the treatment. He did, however, note the drug's harsh side effects, including a rash that caused significant skin peeling. Despite these side effects, initial results are encouraging the medical community and patients. Why it matters. Pancreatic cancer is one of the deadliest forms of cancer, with only about 13% of patients surviving five years after diagnosis. This survival rate has remained relatively stagnant despite advancements in treating other cancers, making the unmet need for new therapies critically important. RBC Capital Markets analyst Leonid Timashev described RevMed's drug as potentially the biggest breakthrough in pancreatic cancer ever, highlighting the significance of a targeted treatment. Daraxonrasib aims to address the core mechanisms driving tumor growth in most pancreatic cancer cases, offering hope for improved outcomes. The broad targeting action of daraxonrasib on RAS mutations, while beneficial in attacking the cancer, also presents challenges. RAS proteins are widespread throughout the body, particularly in the skin, and the drug doesn't differentiate between mutated and normal RAS proteins. This leads to side effects such as rashes, as experienced by Senator Sasse. RevMed acknowledges these side effects but states that most rash cases have been low grade, and no patients have discontinued treatment due to them. The company describes reports of bleeding rashes as uncommon. What comes next. RevMed is proceeding with caution in its drug development, acknowledging the potential risks associated with daraxonrasib's broad RAS-targeting mechanism. CEO Mark Goldsmith noted the company started with a very low dose and gradually increased it, carefully monitoring patient tolerance. The company's scientists predicted that at 80 milligrams, tumors would start to shrink, a milestone they anxiously anticipated. The upcoming release of Phase 3 trial results will be crucial in determining the long-term efficacy and safety profile of daraxonrasib. Positive outcomes could lead to regulatory approval and make the drug available to a broader patient population. Continued monitoring for adverse effects and refinement of dosing strategies will also be essential to optimize treatment outcomes and improve patient quality of life. The drug's potential impact on the pharmaceutical landscape as a targeted therapy is significant. Faq. What is daraxonrasib and how does it work? What are the potential side effects of daraxonrasib? What stage of development is daraxonrasib in?
Sasse spotlights potential pancreatic cancer breakthrough. health April 10, 2026 health pancreatic cancer daraxonrasib Revolution Medicines Former Senator Ben Sasse's experience with Revolution Medicines' daraxonrasib has brought attention to a possible breakthrough in pancreatic cancer treatment, a disease with historically poor survival rates. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, an experimental drug that may become the first targeted treatment for pancreatic cancer. The company anticipates releasing results from a Phase 3 trial soon. Former Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer, is currently taking daraxonrasib. Sasse reported that his tumors have shrunk by 76% since starting the treatment, although he also noted significant side effects, including a severe rash. Sasse's public disclosure of his treatment has drawn significant attention to RevMed and its drug. The potential of daraxonrasib has already boosted RevMed's stock by nearly 185% over the past year, making the company an attractive acquisition target. The drug broadly targets RAS mutations, found in nearly 90% of pancreatic cancer cases. These mutations drive tumor growth, making them a key target for cancer therapy. While Sasse's experience is anecdotal, it has fueled optimism surrounding the drug's potential efficacy. Why it matters. Pancreatic cancer is one of the deadliest major cancers, with only 13% of patients surviving five years after diagnosis. This grim statistic has remained largely unchanged despite advancements in treating other cancers. Currently, there is no targeted treatment specifically for pancreatic cancer. Daraxonrasib represents a significant potential advancement because it directly targets the RAS mutations that are central to the disease's progression. RBC Capital Markets analyst Leonid Timashev described the drug as potentially the biggest breakthrough in pancreatic cancer ever. The drug's mechanism of action, while promising, also contributes to its side effects. RAS proteins are present throughout the body, and daraxonrasib cannot differentiate between mutated and normal RAS proteins. This broad activity leads to side effects like the rash experienced by Sasse. Despite these side effects, RevMed reports that most rash cases have been low grade, with no patients discontinuing treatment as a direct result. However, severe cases, including those with bleeding, have been reported anecdotally by clinical trial investigators. What comes next. RevMed is nearing the release of its Phase 3 trial results, which will be crucial in determining the drug's efficacy and safety profile. The company's initial cautious approach to dosing reflects concerns about tolerability, as daraxonrasib's broad activity against RAS proteins could lead to severe side effects. CEO Mark Goldsmith explained the painstaking process of gradually escalating the dose while closely monitoring patient response. The company's scientists had predicted that tumor shrinkage would begin at 80 milligrams. If the Phase 3 trial results are positive, daraxonrasib could become the first targeted treatment for pancreatic cancer, potentially transforming the prognosis for patients. The drug's success could also make RevMed a prime acquisition target for larger pharmaceutical companies. However, longer-term data will be required to understand the extent of rash severity and other side effects, and to ascertain whether daraxonrasib has lasting impact on survival rates. Further studies and patient testimonials will be essential to fully measure the efficacy and tolerability of daraxonrasib. Related topics on gab.ae: ai Faq. What is daraxonrasib? What are the side effects of daraxonrasib? What impact has the drug had on the company stock?
Revolution Medicines shares have declined 8.8% in the month following its latest earnings report, underperforming the S&P 500. The biotech company reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company currently has no approved products or revenue. Research and development expenses rose 57% year over year to $294.9 million, driven by higher clinical study and manufacturing costs. General and administrative expenses increased more than 136% to $66.7 million. For 2026, Revolution Medicines expects operating expenses between $1.6 billion and $1.7 billion. Since the earnings release, analyst estimates have trended downward, with the consensus estimate shifting 7.21% lower. The stock maintains a Zacks Rank of Hold.
Revolution Medicines to showcase progress across RAS(ON) targeted oncology pipeline with multiple presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026 in San Diego. The presentations will include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D mutant non-small cell lung cancer, which will be featured in a plenary session. The company will also present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with first line metastatic pancreatic ductal adenocarcinoma (PDAC), including monotherapy data and daraxonrasib plus chemotherapy combination data, the latter of which will be featured in a mini-symposium session. Additional presentations will highlight preclinical research supporting a new class of mutant-targeted catalytic RAS(ON) inhibitors, designed to maintain antitumor activity in the setting of emergent resistance. Together, these presentations reflect the breadth of Revolution Medicines' RAS(ON)-focused development strategy, spanning clinical studies across multiple tumor types and ongoing discovery efforts to address resistance and expand therapeutic opportunities for patients with RAS-driven cancers. Details of the presentations are listed below. Revolution Medicines Invited Presentation: | Title: | Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors | | Presenter: | Mallika Singh, Ph.D., Revolution Medicines | | Session: | How KRAS Inhibitors Got to the Clinic: From Discovery to Patient Benefit | | Date/Time: | April 18; 3:00 p.m. - 3:20 p.m. PST | | / | / | Revolution Medicines Oral Presentation: | Title: | Preliminary Safety and Clinical Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer (NSCLC) | | Presenter: | Jonathan Reiss, M.D., UC Davis Comprehensive Cancer Center | | Abstract Number: | CT021 | | Session: | New Frontiers in Precision Oncology | | Date/Time: | April 19; 1:30 p.m. - 1:45 p.m. PST | | / | / | Revolution Medicines Mini Symposiums: | Title: | Daraxonrasib plus Chemotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC) | | Presenter: | Brian Wolpin, M.D., Dana-Farber Cancer Institute | | Abstract Number: | LB407 | | Session: | Late-Breaking Research | | Date/Time: | April 21; 4:05 p.m. - 4:20 p.m. PST | | Title: | Discovery of a New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors with Retained Antitumor Activity in Setting of Emergent Resistance Due to Elevated RAS Flux | | Presenter: | Jacqueline (Jan) Smith, Ph.D., Revolution Medicines | | Abstract Number: | 6782 | | Session: | Targeted Protein Degradation and Non-canonical Oncogenic Signaling | | Date/Time: | April 21; 4:05 p.m. - 4:20 p.m. PST | | / | / | Revolution Medicines Posters: | Title: | RAS(ON) Inhibition in both Cancer and Immune Cells by Daraxonrasib Drives Antitumor Immunity | | Presenter: | Nataliya Shifrin, Ph.D., Revolution Medicines | | Abstract Number: | 2831 | | Session: | Immune Mechanisms Invoked by Other Therapies and Exposures | | Date/Time: | April 20; 2:00 p.m. - 5:00 p.m. PST | | Title: | RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-mutant NSCLC | | Presenter: | Ferdinandos Skoulidis, M.D., Ph.D., MRCP, MD Anderson Cancer Center | | Abstract Number: | CT215 | | Session: | Late-Breaking Research | | Date/Time: | April 21; 9:00 a.m. - 12:00 p.m. PST | | Title: | Daraxonrasib Monotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma | | Presenter: | Eileen O'Reilly, M.D., Memorial Sloan Kettering Cancer Center | | Abstract Number: | LB337 | | Session: | Late-Breaking Research: Clinical Research 3 | | Date/Time: | April 21; 2:00 p.m. - 5:00 p.m. PST | | Title: | RAS(ON) Multi-Selective Inhibitors Stimulate the Hydrolysis of RAS-GTP to RAS-GDP and Drive Synergistic Combination Benefit with KRAS(OFF) Inhibitors in G12 Mutant Tumors | | Presenter: | Kyle Seamon, Ph.D., Revolution Medicines | | Abstract Number: | 5696 | | Session: | Mechanisms of Anticancer Drug Action | | Date/Time: | April 21; 2:00 p.m. - 5:00 p.m. PST | | / | / | Collaborator Mini Symposium: | Title: | Active RAS Inhibition Intercepts Pancreas Cancer in Mice | | Presenter: | Ben Stanger, M.D., Ph.D., Penn Pancreatic Cancer Research Center | | Abstract Number: | LB406 | | Session: | Late-Breaking Research | | Date/Time: | April 21; 3:50 p.m. - 4:05 p.m. PST | | / | / | About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding the company's development strategy and its ability to build or advance its portfolio and R&D pipeline; progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company's candidates being studied; and the ability of the company's RAS(ON) inhibitors to maintain antitumor activity in the setting of emergent resistance. Forward-looking statements are typically, but not always, identified by the use of words such as "aims," "anticipate," "believe," "estimate," "expect," "plan," "potential," "project," "up to," "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company's development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company's programs' development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company's business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 25, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events. Revolution Medicines Media & Investor Contact: [email protected] [email protected]